<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02116998</url>
  </required_header>
  <id_info>
    <org_study_id>GEN-004-002</org_study_id>
    <secondary_id>2014-000944-13</secondary_id>
    <nct_id>NCT02116998</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GEN-004, a Pneumococcal Protein Subunit Vaccine, on Colonization Following Intranasal Challenge With S. Pneumoniae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genocea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genocea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study. Eligible subjects will be&#xD;
      randomized in a 1:1 ratio to receive GEN-004 with adjuvant or placebo. Each subject will&#xD;
      receive up to 3 doses at 4 week intervals.&#xD;
&#xD;
      Following the third dose, subjects will be inoculated intranasally with S. pneumoniae&#xD;
      serotype 6B. Nasal washes to identify S. pneumoniae colonization will be obtained&#xD;
      pre-inoculation, and then 2, 7 and 14 days after inoculation.&#xD;
&#xD;
      Subjects will also be monitored for safety and tolerability throughout the dosing period, and&#xD;
      then for 12 months after their last dose.&#xD;
&#xD;
      The purpose of this study is to evaluate the effectiveness of GEN-004 in reducing&#xD;
      colonization rates and magnitude of colonization following the S. pneumoniae challenge.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of GEN-004 with aluminum hydroxide in healthy adult subjects to reduce nasopharyngeal colonization following intranasal inoculation with S. pneumoniae serotype 6 as measured by proportion of colonized subjects</measure>
    <time_frame>56 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of GEN-004 with aluminum hydroxide</measure>
    <time_frame>56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of S. pneumoniae colonization through 14 days after inoculation</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of GEN-004 with aluminum hydroxide, as measured by TH17 (IL-17) and IgG responses to the vaccine antigens in sera and nasal fluid</measure>
    <time_frame>56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of GEN-004 on the density of colonization as measured by S. pneumoniae colony forming units (CFUs) post-inoculation</measure>
    <time_frame>56 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Pneumococcal Infections</condition>
  <condition>Pneumonia, Pneumococcal</condition>
  <arm_group>
    <arm_group_label>GEN-004 with Aluminum Hydroxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEN-004 with Aluminum Hydroxide Adjuvant</intervention_name>
    <description>GEN-004: 100 µg of each antigen, with adjuvant, 350 µg aluminum hydroxide, administered as a 0.5 mL intramuscular (IM) injection.&#xD;
GEN-004 is a recombinant S. pneumoniae protein subunit vaccine consisting of 3 recombinant T cell antigens:&#xD;
GB104: ABC transporter, substrate-binding protein&#xD;
GB144: Maltose/maltodextrin binding protein, ABC transporter&#xD;
GB152: Hypothetical protein&#xD;
GEN-004 is filled in 2 mL vials containing 0.5 mL (350 µg/mL of each antigen).&#xD;
Aluminum hydroxide adjuvant is filled in 2 mL vials containing 1 mL at a concentration of 5 mg/mL.</description>
    <arm_group_label>GEN-004 with Aluminum Hydroxide</arm_group_label>
    <other_name>GEN-004</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: normal saline, 0.5 mL per dose, IM.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
    <other_name>Normal saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Streptococcus pneumoniae inoculation</intervention_name>
    <description>Intranasal inoculation of S. Pneumoniae (80,000 CFU/100μl per nostril) serotype 6B.</description>
    <arm_group_label>GEN-004 with Aluminum Hydroxide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>S. Pneumoniae</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and non-pregnant females, ages 18 to 55 years inclusive.&#xD;
&#xD;
          -  Willing and able to provide written informed consent.&#xD;
&#xD;
          -  Fluent English speakers only (for safety reasons)&#xD;
&#xD;
          -  Willing to perform and comply with all study procedures including attending clinic&#xD;
             visits as scheduled.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior vaccination with pneumococcal vaccine.&#xD;
&#xD;
          -  History of invasive pneumococcal disease (i.e., sepsis, meningitis or pneumonia with&#xD;
             bacteremia).&#xD;
&#xD;
          -  Close contact with at risk individuals (young children [under 5years],&#xD;
             immunosuppressed adults, elderly, chronic ill health).&#xD;
&#xD;
          -  Current smoker or significant smoking history (&gt;10 pack years).&#xD;
&#xD;
          -  Pregnant or breast-feeding woman.&#xD;
&#xD;
          -  Women of child-bearing potential (WOCBP) who are deemed not to have sufficient,&#xD;
             effective birth control in place for 1 month prior to vaccination and 1 month after&#xD;
             the final vaccination.&#xD;
&#xD;
          -  Allergy to penicillin or amoxicillin.&#xD;
&#xD;
          -  Any screening laboratory value &gt; Grade 1&#xD;
&#xD;
          -  Positive serologic test for HIV-1 or hepatitis C infection; positive hepatitis B&#xD;
             surface antigen (HBsAg).&#xD;
&#xD;
          -  Asthma (on regular medication) or other respiratory disease.&#xD;
&#xD;
          -  Immunocompromised individuals, including those receiving corticosteroids or other&#xD;
             immunosuppressive agents.&#xD;
&#xD;
          -  Presence or history of auto-immune disease (refer to Appendix 4) regardless of current&#xD;
             treatment.&#xD;
&#xD;
          -  No antibiotic treatment within 1 week of inoculation&#xD;
&#xD;
          -  Previous involvement in EHPC study inoculated with pneumococcal bacteria&#xD;
&#xD;
          -  In any other clinical trial unless in observational stage or follow-up&#xD;
&#xD;
          -  Diabetes, type 1 or type 2.&#xD;
&#xD;
          -  Other active, uncontrolled co-morbidities that, in the opinion of the Investigator&#xD;
             would make the subject unsuitable for the study or unable to comply with the study&#xD;
             requirements.&#xD;
&#xD;
        NOTE: Subjects who are taking a medication to control an underlying co-morbidity may be&#xD;
        enrolled if there have been no changes to their medication within 60 days prior to first&#xD;
        dose of Study Drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Fitzgerald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Liverpool University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital, Liverpool School of Tropical Medicine</name>
      <address>
        <city>Liverpool</city>
        <zip>L35QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 11, 2014</study_first_submitted>
  <study_first_submitted_qc>April 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2014</study_first_posted>
  <disposition_first_submitted>February 13, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>February 13, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 15, 2018</disposition_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GEN-004</keyword>
  <keyword>Aluminum hydroxide</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Streptococcus pneumoniae</keyword>
  <keyword>Pneumococcal Infections</keyword>
  <keyword>Strep pneumoniae</keyword>
  <keyword>Pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumococcal Infections</mesh_term>
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

